|
| Title:
|
Randomized, Double-Blind, Placebo-Controlled Trial of Raloxifene on Endothelial Reactivity in Healthy Post-Menopausal Women |
| Status:
|
Completed |
| Topic:
|
Cardiovascular Health / Endothelial Function* |
| Funding Source:
|
Eli Lilly & Co., Inc. |
| Funding Period:
|
4/99-5/00 |
| Study Design:
|
Randomized, Double-Blind, Placebo-Controlled Crossover Trial |
| Purpose:
|
Design: Randomized, Double-Blind, Placebo-Controlled Crossover Trial Purpose: To assess the effects of raloxifene (a synthetic estrogen receptor modulator) on blood vessel performance in healthy post-menopausal women. Raloxifene is commonly prescribed for osteoporosis prevention in post-menopausal women; however, cardioprotective effects have not been studied to date. |
| Further Study Details:
|
The 20 women enrolled in this study were assigned to 2 treatments – raloxifene (60 mg) or placebo daily for 6 weeks. Following each treatment assignment, participants underwent BARS and laser Doppler velocimetry (LDV) testing. |
| Findings:
|
Treatment with raloxifene was shown to improved blood vessel reactivity as compared to placebo, thus suggesting that raloxifene may have a cardioprotective effect in this population. Additionally, raloxifene was not associated with any more side effects than placebo. |
| Eligibility:
|
Healthy, post-menopausal woman not taking hormone replacement therapy |